GBA-associated Parkinson's disease: Reduced survival and more rapid progression in a prospective longitudinal study

Movement Disorders

Volumn 30, Issue 3, 2015, Pages 407-411

  Brockmann, Kathrin ^a,b,c   Srulijes, Karin ^a,b   Pflederer, Sylvia ^a   Hauser, Ann Kathrin ^a,b   Schulte, Claudia ^a,b   Maetzler, Walter ^a,b   Gasser, Thomas ^a,b   Berg, Daniela ^a,b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^c Graduate School of Cellular and Molecular Neuroscience   (Germany)

Author keywords

Dementia; GBA; Parkinson; Progression; Survival

Indexed keywords

LEVODOPA; GLUCOSYLCERAMIDASE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; GBA GENE; GENE; GENE MUTATION; GENETIC SCREENING; HETEROZYGOTE; HUMAN; LONGITUDINAL STUDY; MOTOR DYSFUNCTION; MUTATIONAL ANALYSIS; ONSET AGE; PARKINSON DISEASE; PRIORITY JOURNAL; REGRESSION ANALYSIS; SURVIVAL; UNIFIED PARKINSON DISEASE RATING SCALE; AGED; CASE CONTROL STUDY; COHORT ANALYSIS; FEMALE; GENETICS; MALE; MIDDLE AGED; MORTALITY; MUTATION;

ADULT; AGED; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; GLUCOSYLCERAMIDASE; HUMANS; MALE; MIDDLE AGED; MUTATION; PARKINSON DISEASE; REGRESSION ANALYSIS;

EID: 84924569948     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26071     Document Type: Article

References (15)

1. Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R. Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N Engl J Med 2004;351:1972-1977.
2. Sidransky E, Nalls MA, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 2009;361:1651-1661.
3. Brockmann K, Srulijes K, Hauser AK, et al. GBA-associated PD presents with nonmotor characteristics. Neurology 2011;77:276-280.
4. Forsaa EB, Larsen JP, Wentzel-Larsen T, Alves G. What predicts mortality in Parkinson disease?: a prospective population-based long-term study. Neurology 2010;75:1270-1276.
5. Litvan I, Bhatia KP, Burn DJ, et al. Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord 2003;18:467-486.
6. The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations. Mov Disord 2003;18:738-750.
7. Goetz CG, Poewe W, Rascol O, et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord 2004;19:1020-1028.
8. Hoops S, Nazem S, Siderowf AD, et al. Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology 2009;73:1738-1745.
9. Kuhner C, Burger C, Keller F, Hautzinger M. [Reliability and validity of the Revised Beck Depression Inventory (BDI-II). Results from German samples]. Der Nervenarzt 2007;78:651-656.
10. Williams-Gray CH, Mason SL, Evans JR, et al. The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort. J Neurol Neurosurg Psychiatry 2013;84:1258-1264.
11. Winder-Rhodes SE, Evans JR, Ban M, et al. Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort. Brain 2013;136:392-399.
12. Neumann J, Bras J, Deas E, et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain 2009;132:1783-1794.
13. Mazzulli JR, Xu YH, Sun Y, et al. Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 2011;146:37-52.
14. Schondorf DC, Aureli M, McAllister FE, et al. iPSC-derived neurons from GBA1-associated Parkinson's disease patients show autophagic defects and impaired calcium homeostasis. Nat Commun 2014;5:4028.
15. Gegg ME, Burke D, Heales SJ, et al. Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. Ann Neurol 2012;72:455-463.